Catalyst OrthoScience Received 510(k) in March 2021, Conducting Limited User Release Through Q2 2021

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, today announced the first surgeries using the new ArcherR1 Reverse Shoulder System. In March, the company received FDA 510(k) clearance and has kicked off a limited user release in Q2 2021. A commercial launch is planned for later in 2021. With the introduction of the Archer R1 system, Catalyst is addressing the two fastest growing segments of the shoulder arthroplasty market – stemless anatomic and reverse TSA.

“Reverse shoulder arthroplasty encompasses more than 60 percent of the shoulder arthroplasty market,” said Brian K. Hutchison, chairman and CEO of Catalyst. “These first surgeries with our Archer R1 reverse system went well, and we’re excited by the feedback we’re getting from the initial surgeon users.”

“We designed for the first time a single-tray reverse shoulder arthroplasty system which harnesses the best features of existing systems while maximizing ease-of-use, efficiency and bone preservation, among other features,” said John G. Costouros, MD, chief of shoulder surgery at the Institute for Joint Restoration and Research, past professor Stanford University.  “My early experience has been exceptional.”

“These are very exciting times, working with the new Archer R1 system” said Zachary Leitze, MD, orthopedic surgeon at Intermountain Medical Group, St. George, Utah. “The system allowed for an efficient workflow through my surgeries. The humeral components perfectly centered in the metaphyseal cut, the glenoid prep was uncomplicated and the base plate secured well.”

“I am impressed with the workflow,” said Steven Goldberg, MD, orthopedic surgeon at Physicians Regional Medical Center, Naples, Fla. “The real bonus is not from what the system has, but what’s gone - the careful elimination of redundant steps or rarely used tools to make this incredibly efficient for the O.R. team.”

Catalyst’s Archer R1 reverse system is a single-tray arthroplasty system that was engineered to combine the most beneficial and evidence-based attributes of reverse shoulder arthroplasty design. The system offers surgeon-targeted implant positioning, a streamlined and versatile system, and bone sparing implants.

The system is a total shoulder prosthesis designed for patients experiencing severe shoulder arthritis in conjunction with a grossly deficient or non-functional rotator cuff. In a reverse shoulder system, the design is inverted compared to a traditional anatomic total shoulder prosthesis where the articulating sphere is on the glenoid side of the joint and the mating insert is fixed into the humeral stem implant.

Catalyst is one of the fastest-growing players in the anatomic stemless total shoulder arthroplasty market, starting with its popular Archer™ CSR Total Shoulder System. The Archer CSR system combines innovative components and unique instrumentation to bring about a precise, accurate restoration of the shoulder. It features a stemless, ellipsoid humeral component that is engineered to accurately replace the elliptical shape of the patient’s native non-spherical ​humeral head.

We are looking forward to the October 7 episode of Grey’s Anatomy that features Simbionix simulators from Surgical Science. More on the GI Mentor: https://t.co/fAkg5l9rbo
#Simbionix #GreysAnatomy #endoscopy #simulation #medicalsimulation #MedEd

The Competition Module on the recently unveiled ENDO Mentor Suite https://t.co/ZxSu7GBMmx was well received at SAGES. "The simulator was really fun to use and had me using the same techniques I’ve been trained to use on real patients!" said competition winner, Nicholas Rawson, DO

Is your organization thinking about deploying #smartphones for #nurses? Stop✋🏽what you're doing and read our blog to get some key insights about mobilizing care team communication by selecting the right #mobiledevices for nurses.📱More here: https://t.co/JB6yOZ57DY

We are #hiring a VP of Americas Enterprise Sales who will own the go-to-market organization (GTM) for our Enterprise portfolio for both direct and indirect sales motions. Click below to learn more & apply today! https://t.co/za5X2cksrS

Accurate tissue diagnosis improves therapeutics and patient outcomes. With NICO’s intra- operative tissue collection and biological preservation, more in-tact and viable tissue is collected. #niconeurosurgery #neurosolutions

Our Integrated System - NICO Corporation

NICO technologies are part of an integrated systems solution to ACCESS, ILLUMINATE, REMOVE, COLLECT and PRESERVE that address unmet needs of the neuro...

ow.ly